Past Contracts
Previous years' contract solicitations can be viewed here:
PHS 2020 included 16 contract topics released by NCI:
PHS 2019 included 15 contract topics released by NCI:
- 382 - Integrated Subcellular Microscopy and ‘Omics in Cancer Cell Biology
- 383 - Smart, Multi-Core Biopsy Needle
- 384 - Digital Healthcare Platform to Reduce Financial Hardship for Cancer Patients
- 385 - Leveraging Connected Health Technologies to Address and Improve Health Outcomes of Long-Term Cancer Survivors
- 386 - Novel Approaches for Local Delivery of Chemopreventive Agents
- 387 - Multiplexed Preclinical Tools for Longitudinal Characterization of Immunological Status in Tumor and its Microenvironment
- 388 - In vitro Diagnostic for the Liver Flukes Opisthorchis viverrini and Clonorchis sinensis
- 389 - Development of Artificial Intelligence (AI) Tools to Understand and Duplicate Experts' Radiation Therapy Planning for Prostate Cancer
- 390 - Clonogenic High-Throughput Assay for Screening Anti-Cancer Agents and Radiation Modulators
- 391 - Drugs or Devices to Exploit the Immune Response Generated by Radiation Therapy
- 392 - Clinical Trials of Systemic Targeted Radionuclide Therapies
- 393 - Sensing Tools to Measure Biological Response to Radiotherapy
- 394 - Combinatory Treatment Modalities Utilizing Radiation to Locally Activate or Release Systemically Delivered Therapeutics
- 395 - Targeted Therapy for Cancer- and Cancer Therapy-Related Cachexia
- 396 - Imaging for Cancer Immunotherapies
*Solicitation Amendment 1; Solicitation Amendment 2
** Guide Notice: NOT-OD-18-209 for PHS 2019-1
PHS 2018 included 12 contract topics released by NCI:
- 370 - Targeted Therapy for Cancer- and Cancer Therapy-Related Cachexia
- 371 - Drugs to Exploit the Immune Response Generated by Radiation Therapy
- 372 - Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics
- 373 - Tools and Technologies for Monitoring RNA Modifications
- 374 - Novel Approaches for Local Delivery of Chemopreventive Agents
- 375 - Diagnostic Imaging for Cancer Immunotherapies
- 376 - Imaging-Based Tools for Longitudinal and Multi-Dimensional Mapping of the Tumor and its Microenvironment
- 377 - Bridging the Guideline Implementation Gap: Clinical Decision-Support to Improve Cancer Symptom Management
- 378 - Mobile Application for Surveillance of Post-Radiation Therapy Health-Related Quality of Life
- 379 - Software Enabling Data Integration from Wearable Sensors to Generate Novel Analytics for Cancer Patients
- 380 - Computer Aided Decision Support for Radiation Oncology
- 381 - Development of Artificial Intelligence (AI) Tools to Understand and Duplicate Experts’ Radiation Therapy Planning for Prostate Cancer
** Q&A Amendment 1; Q&A Amendment 2; Q&A Amendment 3
PHS 2017 included 15 contract topics released by NCI:
- 355 - Cell and Animal-Based Models to Advance Cancer Health Disparity Research
- 356 - Tools and Technologies for Monitoring RNA
- 357 - Innovative Tools for Interrogating Tumor Microenvironment Dynamics
- 358 - Modulating the Microbiome to Improve Therapeutic Efficacy of Cancer Therapeutics
- 359 - Technologies for Differential Isolation of Exosomes and Oncosomes
- 360 - Manufacturing Innovation for the Production of Cell-Based Cancer Immunotherapies
- 361 - Highly Innovative Tools for Quantifying Redox Effector Dynamics in Cancer
- 362 - Informatics Tools to Measure Cancer Care Coordination
- 363 - Connecting Cancer Caregivers to Care Teams: Digital Platforms to Support Informal Cancer Caregiving
- 364 - Methods and Software for Integration of Cancer Metabolomic Data with Other –Omic and Imaging Data
- 365 - Imaging Informatics Tools and Resources for Clinical Cancer Research
- 366 - Clonogenic High-Throughput Assay for Screening Anti-Cancer Agents and Radiation Modulators
- 367 - Predictive Biomarkers to Improve Radiation Treatment
- 368 - Molecularly Targeted Radiation Therapy for Cancer Treatment
- 369 - Development of Pediatric Cancer Drug Delivery Devices
** Q&A Amendment 1, released on September 22, 2016.
*** Guide Notice (NOT-OD-16-123) for PHS 2017-1.
PHS2016 included 14 contract topics released by NCI:
PHS2015 included 7 contract topics released by NCI:
- 336 - Development of Novel Therapeutic Agents That Target Cancer Stem Cells
- 337 - Cell-Free Nucleic Acid-Based Assay Development for Cancer Diagnosis
- 338 - Predictive Biomarkers of Adverse Reactions to Radiation Treatment
- 339 - Systemic Targeted Radionuclide Therapy For Cancer Treatment
- 340 - Validation of Mobile Technologies for Clinical Assessment, Monitoring, and Intervention
PHS2014 included 8 contract topics released by NCI:
PHS2013 included 13 contract topics released by NCI: